Evaluation of the efficiency and safety of lipid-lowering therapy in comorbid patients


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The efficacy and safety of pitavastatin at doses of 2 and 4 mg daily and rosuvastatin at a dose of 10 mg daily were investigated in comorbid patients with first-time ischemic stroke.

Full Text

Restricted Access

About the authors

V. Shishkova

Center for Speech Pathology and Neurorehabilitation

Email: veronika-1306@mail.ru
Candidate of Medical Sciences

A. Remennik

Center for Speech Pathology and Neurorehabilitation

Candidate of Medical Sciences

L. Zotova

Center for Speech Pathology and Neurorehabilitation

E. Zotova

Center for Speech Pathology and Neurorehabilitation

References

  1. Шальнова С.А., Деев А.Д. Тенденции смертности в России в начале XXI века (по данным официальной статистики) // Кардиоваск. тер. и профилакт. -2011; 10 (6): 5-10.
  2. Оганов Р.Г., Масленникова Г.Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения // Кардиоваск. тер. и профилакт. - 2012; 11 (2): 5-10.
  3. Рекомендации ЕОК/ЕОА по диагностике и лечению дислипидемий 2016 // Рос. кардиол. журн. - 2017; 5 (145): 7-77.
  4. Barylski M., Nikolic D., Banach M. et al. Statins and New-Onset Diabetes // Current Pharmaceutical Design. - 2013; 19: 1-8.
  5. Sattar N., Preiss D., Murray H. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials // Lancet. - 2010; 375: 735-42.
  6. Ishikawa M., Okajima F., Inoue N. et al. Distinct effects of pravastatin, atorvastatin and simvastatin on insulin secretion from a beta-cell line, MIN6 cells // J. Atheroscler. Thromb. - 2006; 13 (6): 329-35.
  7. Yamakasava T., Takano T., Tanaka S. et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus // J. Atheroscler. Thromb. - 2008; 15: 269-75.
  8. Boyd C. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for performance // JAMA. - 2005; 294 (6): 716-24.
  9. Шишкова В.Н. Коморбидность и полипрагмазия // Врач. - 2017; 7: 26-30.
  10. Mukhtar R., Reid J., Reckless J. Pitavastatin // Int. J. Clin. Pract. - 2005; 59: 239-52.
  11. Weng T., Yang Y., Lin S. et al. A systematic review and meta-analysis on the therapeutic equivalence of statins // J. Clin. Pharm. Ther. - 2010; 35: 139-51.
  12. da Silva P. Are all statins the same?: Focus on the efficacy and tolerability of pitavastatin // Am. J. Cardiovasc. Drug. - 2011; 11: 93-107.
  13. Corsini A., Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins ’Achilles’ heel? // Curr. Med. Res. Opin. - 2011; 27: 1551-62.
  14. Kurihara Y., Douzono T., Kawakita K. et al. A large-scale, long-term, prospective postmarketing surveillance olpitavastatin (LIVALO® Tablet) - LIVALO Effectiveness and Safety (LIVES) Study // Jpn. Pharmacol. Ther. - 2008; 36: 709-31.
  15. Шишкова В.Н., Капустина Л.А. Проблемы коморбидного пациента: как выбрать правильный статин // Фармакотерапия. - 2017; 17: 14-23.
  16. Takayama K., Taki W., Toma N. et al. Effect of Pitavastatin on Preventing Ischemic Complications with Carotid Artery Stenting: A Multicenter Prospective Study - EPOCH-CAS Study // Cardiovasc. Intervent. Radiol. - 2014; 37: 1436-43.
  17. Катапано А., Кухарчук В.В., Сергиенко И.В. и др. Питавастатин -современный статин для коррекции дислипидемии и риска сердечнососудистых осложнений. Резолюция экспертного совета // Атеросклероз и дислипидемии. - 2017; 2: 104-6.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies